16 Oct Decentralized clinical trials back in the spotlight thanks to new FDA guidance
The Association of Clinical Research Professionals (ACRP)
Just when it seemed as if decentralized clinical trials (DCTs) were in danger of becoming “yesterday’s news” in light of all the attention being paid lately to applications of artificial intelligence in the clinical research enterprise, the tables have turned, if perhaps only briefly, thanks to the release of finalized new U.S. Food and Drug Administration (FDA) regulatory guidance on DCTs.
In addition to keeping its DCT Resource Center up to date, ACRP invited two seasoned commentators on regulatory and compliance trends in the industry to weigh in on the guidance. Read more …